Company Profile

UPL has reported results for fourth quarter and year ended March 31, 2021.

The company has reported net loss at Rs 132 crore for the quarter under review as compared to net loss of Rs 126 crore for the same quarter in the previous year. Total income of the company increased by 30.00% at Rs 2630 crore for Q4FY21 as compared Rs 2023 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 72.28% in its net profit attributed to the Equity holders at Rs 1063 crore for the quarter under review as compared to Rs 617 crore for the same quarter in the previous year. Total income of the company increased by 15.08% at Rs 12845 crore for Q4FY21 as compared Rs 11162 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported a fall of 52.28% in its net profit at Rs 220 crore as compared to Rs 461 crore for the previous year. However, total income of the company increased by 12.92% at Rs 11458 crore for year under review as compared to Rs 10147 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 61.66% in its net profit attributed to the owners at Rs 2871 crore as compared to Rs 1776 crore for the previous year. Total income of the company increased by 8.62% at Rs 38952 crore for year under review as compared to Rs 35860 crore for year ended March 31, 2020.

UPL is currently trading at Rs. 747.50, up by 55.90 points or 8.08% from its previous closing of Rs. 691.60 on the BSE.

The scrip opened at Rs. 709.85 and has touched a high and low of Rs. 757.60 and Rs. 707.55 respectively. So far 1490445 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 757.60 on 14-May-2021 and a 52 week low of Rs. 336.55 on 20-May-2020.

Last one week high and low of the scrip stood at Rs. 757.60 and Rs. 625.25 respectively. The current market cap of the company is Rs. 57019.69 crore.

The promoters holding in the company stood at 27.96%, while Institutions and Non-Institutions held 53.76% and 10.12% respectively.

UPL has reported results for fourth quarter and year ended March 31, 2021.

The company has reported net loss at Rs 132 crore for the quarter under review as compared to net loss of Rs 126 crore for the same quarter in the previous year. Total income of the company increased by 30.00% at Rs 2630 crore for Q4FY21 as compared Rs 2023 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 72.28% in its net profit attributed to the Equity holders at Rs 1063 crore for the quarter under review as compared to Rs 617 crore for the same quarter in the previous year. Total income of the company increased by 15.08% at Rs 12845 crore for Q4FY21 as compared Rs 11162 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported a fall of 52.28% in its net profit at Rs 220 crore as compared to Rs 461 crore for the previous year. However, total income of the company increased by 12.92% at Rs 11458 crore for year under review as compared to Rs 10147 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 61.66% in its net profit attributed to the owners at Rs 2871 crore as compared to Rs 1776 crore for the previous year. Total income of the company increased by 8.62% at Rs 38952 crore for year under review as compared to Rs 35860 crore for year ended March 31, 2020.

UPL’s subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma for exclusive access to Flupyrimin for rice in Southeast Asia. Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound. Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.

UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.

UPL is currently trading at Rs. 675.50, up by 1.10 points or 0.16% from its previous closing of Rs. 674.40 on the BSE.

The scrip opened at Rs. 678.20 and has touched a high and low of Rs. 687.95 and Rs. 668.05 respectively. So far 329261 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 687.95 on 11-May-2021 and a 52 week low of Rs. 336.55 on 20-May-2020.

Last one week high and low of the scrip stood at Rs. 687.95 and Rs. 619.00 respectively. The current market cap of the company is Rs. 52042.03 crore.

The promoters holding in the company stood at 27.96%, while Institutions and Non-Institutions held 53.76% and 10.12% respectively.

UPL’s subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma for exclusive access to Flupyrimin for rice in Southeast Asia. Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound. Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.

UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.